2.02

1.93% -0.04

Stereotaxis Inc (STXS)

Overview News Price History Option Chain Discussions Forecast Stock Split

Stereotaxis Inc stock is traded at $2.02, with a volume of 512.19K. It is down -1.93% in the last 24 hours and down -14.76% over the past month. Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic magnetic navigation system that enables physicians to complete interventional procedures by providing image guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and therapeutic devices designed to enhance interventional procedures. The company also offers Odyssey solution, a real-time information solution to manage, control, record, and share procedures across networks. In addition, it provides disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company's disposables and other accessories include V-CAS and V-CAS Deflect catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. The company markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to design and develop a next-generation magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.

Previous Close:

$2.06

Open:

$2.05

24h Volume:

512.19K

Relative Volume:

1.23

Market Cap:

$178.78M

Revenue:

$25.14M

Net Income/Loss:

$-21.57M

P/E Ratio:

-7.4815

EPS:

-0.27

Net Cash Flow:

$-12.23M

1W Performance:

-11.39%

1M Performance:

-14.76%

6M Performance:

-9.81%

1Y Performance:

-25.18%

1-Day Range:

$1.93

$2.12

1-Week Range:

$1.93

$2.28

52-Week Range:

$1.66

$3.29

Stereotaxis Inc Stock (STXS) Company Profile

Name

Stereotaxis Inc

Sector

Healthcare (1188)

Industry

Medical Instruments & Supplies (62)

Phone

314-678-6100

Address

4320 Forest Park Avenue, Suite 100, St. Louis, MO

Employee

118

Twitter

@stereotaxis

Next Earnings Date

2025-03-03

Latest SEC Filings

STXS's Discussions on Twitter

Compare STXS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
STXS Stereotaxis Inc	2.01	178.78M	25.14M	-21.57M	-12.23M	-0.27
ISRG Intuitive Surgical Inc	579.13	205.74B	8.35B	2.32B	1.30B	6.41
BDX Becton Dickinson Co	229.45	65.11B	20.64B	1.73B	2.94B	6.02
ALC Alcon Inc	94.72	46.26B	9.91B	1.02B	665.00M	2.05
RMD Resmed Inc	234.67	34.51B	4.93B	1.25B	1.38B	8.47
COO The Cooper Companies, Inc.	92.49	18.19B	3.90B	392.30M	288.10M	1.95

Stereotaxis Inc Stock (STXS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-10-24	Initiated	ROTH MKM	Buy
Jul-12-22	Initiated	Aegis Capital	Buy
Jun-23-22	Initiated	B. Riley Securities	Buy
Jan-05-22	Initiated	Craig Hallum	Buy
Jan-05-22	Initiated	Loop Capital	Buy
May-26-21	Initiated	Piper Sandler	Overweight
Sep-08-20	Initiated	Northland Capital	Outperform
Apr-09-20	Initiated	Cowen	Outperform
Apr-07-20	Initiated	Lake Street	Buy

View All

Stereotaxis Inc Stock (STXS) Latest News

09:30 AM

Earnings call transcript: Stereotaxis Q4 2024 misses forecasts, stock dips By Investing.com - Investing.com UK

09:30 AM

08:45 AM

Stereotaxis announces FDA regulatory submission for MAGiC Sweep catheter - TipRanks

08:14 AM

07:46 AM

Stereotaxis Reports 2024 Full Year Financial Results - The Manila Times

07:46 AM

07:41 AM

Stereotaxis Submits FDA Application for EMAGIN™ 5F, First Robotically Navigated Catheter for Endovascular Procedures - Nasdaq

07:41 AM

07:33 AM

Stereotaxis Submits EMAGIN Catheter for Regulatory Clearance as it Pioneers Robotics for Endovascular Surgery - GlobeNewswire

07:33 AM

Stereotaxis Submits First Ever Robotically Navigated High-Density EP Mapping Catheter for Regulatory Clearance - GlobeNewswire

07:33 AM

07:32 AM

Can Stereotaxis Revolutionize Stroke and Cancer Treatment? New Robotic Catheter Heads to FDA - StockTitan

07:32 AM

07:31 AM

Could This First-Ever Robotic Mapping Catheter Transform Cardiac Procedures? - StockTitan

07:31 AM

07:30 AM

Can Stereotaxis Turn Q4 Momentum Into Sustained Growth After Flat 2024 Results? - StockTitan

07:30 AM

Mar 02, 2025

Stereotaxis, Inc. to Host Earnings Call - ACCESS Newswire

Mar 02, 2025

Mar 01, 2025

Stereotaxis (STXS) to Release Quarterly Earnings on Monday - Defense World

Mar 01, 2025

Feb 28, 2025